FDA: No Medical Benefit From Marijuana
The Food and Drug Administration's statement contradicts a 1999 review by a panel of highly regarded scientists.
The Food and Drug Administration’s statement contradicts a 1999 review by a panel of highly regarded scientists.
WAIT, BEFORE YOU GO…N.Y. Times:
April 21, 2006 F.D.A. Dismisses Medical Benefit From Marijuana By GARDINER HARRIS
WASHINGTON, April 20 — The Food and Drug Administration said Thursday that “no sound scientific studies” supported the medical use of marijuana, contradicting a 1999 review by a panel of highly regarded scientists.
The announcement inserts the health agency into yet another fierce political fight.
Susan Bro, an agency spokeswoman, said Thursday’s statement resulted from a past combined review by federal drug enforcement, regulatory and research agencies that concluded “smoked marijuana has no currently accepted or proven medical use in the United States and is not an approved medical treatment.”
Ms. Bro said the agency issued the statement in response to numerous inquiries from Capitol Hill but would probably do nothing to enforce it.
If you're reading this, you probably already know that non-profit, independent journalism is under threat worldwide. Independent news sites are overshadowed by larger heavily funded mainstream media that inundate us with hype and noise that barely scratch the surface. We believe that our readers deserve to know the full story. Truthdig writers bravely dig beneath the headlines to give you thought-provoking, investigative reporting and analysis that tells you what’s really happening and who’s rolling up their sleeves to do something about it.
Like you, we believe a well-informed public that doesn’t have blind faith in the status quo can help change the world. Your contribution of as little as $5 monthly or $35 annually will make you a groundbreaking member and lays the foundation of our work.
Women
A pharmacist and public health expert explain this new era in contraception.
Technology
Elon Musk's company has been hyping up human trials for years but only after a myriad of scandals around animal testing.
TD Original
In previously unreported statements made at the 2017 International Drug Policy Reform Conference, Rick Doblin, executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS), discussed rumors of secret Pentagon studies with MDMA, as well as the reasons for hesitancy on the part of some government agencies to fund MAPS’ research.
The FDA’s strict guidance on test confirmations is one of several obstacles that has slowed the federal government’s response to COVID-19. The FDA could change its rules to speed things up, but hasn’t.
The agency's OK, four months after it rejected the drug over safety concerns, may stoke questions about standards for clearing medications.
Lack of government oversight has created public health crises including antibiotic-resistant diseases, foodborne illness and flu epidemics.
There are currently no responses to this article.
Be the first to respond.